Evidence map›Paper›PMID 26748387›Full record

ArticleMolecular immunology2016

Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.

Mark D Hicar, Xuemin Chen, Spyros A Kalams, Hakimuddin Sojar, Gary Landucci, Donald N Forthal, Paul Spearman, James E Crowe

Abstract read
In one paragraph

Article in Molecular immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Mark D HicarDepartment of Pediatrics, University at Buffalo, Buffalo, NY 14222, United States; Department of Microbiology and Immunology, University at Buffalo, Buffalo, NY 14222, United States.
Xuemin ChenDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, United States; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, United States.
Spyros A KalamsDepartment of Pathology, Microbiology and Immunology Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Medicine, Vanderbilt, University Medical Center, Nashville, TN 37232, United States.
Hakimuddin SojarDepartment of Pediatrics, University at Buffalo, Buffalo, NY 14222, United States.
Gary LanducciDepartment of Medicine, University of California, Irvine, CA 92668, United States.
Donald N ForthalDepartment of Medicine, University of California, Irvine, CA 92668, United States.
Paul SpearmanDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, United States; Department of Pathology, Microbiology and Immunology Vanderbilt University Medical Center, Nashville, TN 37232, United States; Children's Healthcare of Atlanta, Atlanta, GA 30329, United States.
James E CroweDepartment of Pathology, Microbiology and Immunology Vanderbilt University Medical Center, Nashville, TN 37232, United States; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States. Electronic address: james.crowe@vanderbilt.edu.
Emory University · USUniversity at Buffalo, State University of New York · USUniversity of California, Irvine · USVanderbilt University Medical Center · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD · 2003 to 2011
$10.3M
Clonal Analysis of the Human B Cell Response to HIVU01AI078407 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E · 2008 to 2012
$3.9M
The impact of antibody and pH on female-to-male SIV infectionR01AI102715 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N, MILLER, CHRISTOPHER JAMES · 2012 to 2015
$2.7M
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infectionR01AI125119 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI HICAR, MARK DANIEL · 2016 to 2020
$2.0M
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)K08AI083078 · NIAID · VANDERBILT UNIVERSITY · PI HICAR, MARK DANIEL · 2009 to 2013
$639k
NCATS NIH HHS UL1 TR001414NIAID NIH HHS K08 AI083078NIAID NIH HHS NIH K08 AI083078NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI-054999NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI110527NIAID NIH HHS P30-AI50409NIAID NIH HHS R01 AI-102715NIAID NIH HHS R01 AI102715NIAID NIH HHS R01 AI125119NIAID NIH HHS U01 AI-078407NIAID NIH HHS U01 AI078407
6 · The paper itself

Abstract

Neutralizing antibodies (Abs) are thought to be a critical component of an appropriate HIV vaccine response. It has been proposed that Abs recognizing conformationally dependent quaternary epitopes on the HIV envelope (Env) trimer may be necessary to neutralize diverse HIV strains. A number of recently described broadly neutralizing monoclonal Abs (mAbs) recognize complex and quaternary epitopes. Generally, many such Abs exhibit extensive numbers of somatic mutations and unique structural characteristics. We sought to characterize the native antibody (Ab) response against circulating HIV focusing on such conformational responses, without a prior selection based on neutralization. Using a capture system based on VLPs incorporating cleaved envelope protein, we identified a selection of B cells that produce quaternary epitope targeting Abs (QtAbs). Similar to a number of broadly neutralizing Abs, the Ab genes encoding these QtAbs showed extensive numbers of somatic mutations. However, when expressed as recombinant molecules, these Abs failed to neutralize virus or mediate ADCVI activity. Molecular analysis showed unusually high numbers of mutations in the Ab heavy chain framework 3 region of the variable genes. The analysis suggests that large numbers of somatic mutations occur in Ab genes encoding HIV Abs in chronically infected individuals in a non-directed, stochastic, manner.

Indexed as

MutationAntibodies, MonoclonalAntibodies, NeutralizingB-LymphocytesCell Separationenv Gene Products, Human Immunodeficiency VirusEnzyme-Linked Immunosorbent AssayEpitopesFlow CytometryGenes, ImmunoglobulinHIV AntibodiesHIV InfectionsHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionAntibodies, MonoclonalAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionAntibodiesB cellsHIVHumanMonoclonal antibodiesNeutralization

Identifiers

PMID26748387
PMCPMC4762738
OpenAlexW2201464200

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.